Eli Lilly Receives EU Approval for Amyvid

by Savitha C Muppala on  January 21, 2013 at 10:42 AM Drug News   - G J E 4
Eli Lilly and Company ( LLY ) has announced the approval by the European Commission (EC) for its radioactive diagnostic agent, Amyvid (florbetapir F 18 Injection),.
 Eli Lilly Receives EU Approval for Amyvid
Eli Lilly Receives EU Approval for Amyvid

Amyvid is a shot in the arm for medical specialists as it helps in detecting the density of beta-amyloid neuritic plaques in victims suffering cognitive impairment for instance victims of Alzheimer's disease.

Amyvid had received the approval to be marketed in the U.S in 2012, and now Eli Lilly hopes to introduce it in certain parts of the EU in the next 3 months.

Amyvid is a good bet for the company, as it takes forward its initial objective of developing treatments for Alzheimer's disease. Amyvid promises to be a boon for physicians as it can support diagnostic methods while evaluating patients.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like